[The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
An open randomized study of pharmacoeconomic efficacy of stalevo in patients with Parkinson's disease with motor fluctuations was conducted. The results of the study revealed that the drug substantially reduced motor deficit, increased the "on"-period, decreased the duration and severity of the "off" period, improved the daily activity and quality of life of patients compared to standard therapy with an additional dosage of levodopa/DDC inhibitor. Despite the increase in cost, the use of stalevo in the treatment of Parkinson's disease with motor fluctuations is cost-effective in long-term (already after two years) management of patients.
Levin
O S
OS
Smolentseva
I G
IG
Fedorova
N V
NV
Chigir'
I P
IP
Dokadina
L V
LV
Makhnev
S O
SO
D000978:Antiparkinson Agents / Q000191:economics* / Q000627:therapeutic use*; D002230:Carbidopa / Q000191:economics* / Q000627:therapeutic use*; D002396:Catechols / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007980:Levodopa / Q000191:economics* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000191:economics; D011596:Psychomotor Disorders / Q000150:complications*; D012720:Severity of Illness Index
D000978:Antiparkinson Agents; D002396:Catechols; D004338:Drug Combinations; C481098:Stalevo; D007980:Levodopa; D002230:Carbidopa